Checkpoint Inhibitor denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for checkpoint inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Your Checkpoint Inhibitor — Non-Formulary

UHC's formulary is a tiered list of covered drugs. When a checkpoint inhibitor is denied as "non-formulary," it means the specific agent is not on your plan's formulary at a covered tier — or is excluded entirely. In oncology, this creates a real problem because checkpoint inhibitors are not interchangeable: each has distinct FDA-approved indications, different biomarker eligibility requirements, and different evidence profiles. A formulary alternative may simply not be clinically appropriate for your cancer type.

Federal and state laws provide a formulary exception process specifically for situations where no covered alternative is clinically equivalent.

## Federal Appeal Framework

• Formulary exception request: File this first and simultaneously with the appeal. UHC is required to have a formulary exception process; it must be granted when a covered alternative is contraindicated, likely to be ineffective, or has caused adverse reactions in the patient.
• Internal appeal: File within 180 days; expedited review available for urgent oncology cases.
• ACA §2719 external review: After the internal process, request independent external review within the ~4-month statutory window. External reviewers evaluate whether the plan's formulary exception criteria have been correctly applied.
• ERISA §503 (employer plans): Request the formulary tier placement criteria and the exception policy used to evaluate your request.

## Documentation to Gather

1. Formulary alternatives review: Obtain the list of formulary-covered checkpoint inhibitors or immunotherapy agents on your plan. Ask the oncologist to evaluate each and document in writing why each alternative is not clinically appropriate for this patient's specific diagnosis, biomarker profile, and line of therapy. 2. Biomarker and histology records: The reason a covered alternative is inadequate often lies in the biomarker requirements — document the patient's specific markers and the indication restrictions of the alternative agents. 3. Prescriber medical-necessity letter for the exception: Should state that no covered formulary alternative is clinically equivalent and explain the clinical basis for this conclusion with patient-specific evidence. 4. Applicable NCCN guideline: The oncologist should reference the guideline recommendation for the specific drug in the patient's context to establish that the non-formulary agent is a recommended standard of care. 5. Prior adverse reactions or failures: If the patient has previously tried a formulary alternative and experienced progression or unacceptable toxicity, document this in full detail.

## Criteria-Mapping Structure

Obtain UHC's formulary exception criteria and address each: document why each covered alternative is clinically inappropriate, map the patient's biomarker and histology profile to the requested agent's FDA-approved indication, and attach the guideline support. A formulary exception that is grounded in patient-specific clinical evidence and guideline support is difficult to sustain on external review.